Revolution Medicines, Inc.

Good day, and thank you for standing by. Welcome to the Revolution Medicine's Q3 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Ryan Acy, Senior Vice President of Corporate Affairs. Please go ahead.

Thank you, and welcome everyone to the third quarter 2024 earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer, Dr. Steve Kelsey, our President of R&D, and Jack Anders, our Chief Financial Officer. Dr. Wei Lin, our Chief Medical Officer, will join us for the Q&A portion of today's call. I'd like to inform you that certain statements we make during this call will be forward-looking because such statements deal with future events and are subject to many risks and uncertainties. Actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K and our quarterly report on Form 10-Q that are filed with the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended September 30th, 2024 and recent corporate updates. The press release is available on the investor section of our website at RevMed.com. With that, I'll turn the call over to Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer.

Mark. Thanks, Ryan. It's good to be with you this afternoon. At Revolution Medicines, we are committed to revolutionizing treatment for patients with RAS-addicted cancers through the discovery, development, and delivery of innovative targeted medicines. We believe that we have increasingly been able to demonstrate that our portfolio of RAS-on inhibitors has the potential to provide meaningful impact for patients living with some of the most difficult-to-treat cancers. At the start of the year, we provided a roadmap of strategic development priorities for 2024 focused on our three pioneering Rason inhibitors in clinical development, RMC6236, RMC6291, and RMC9805. The highest priority has been to advance RMC6236, our first-in-class Rason multiselective inhibitor, into its first pivotal trials, one in pancreatic ductal adenocarcinoma, which we refer to as PDAC, and one in non-small cell lung cancer. Our second priority aimed to begin defining the path to expanding the reach of RMC6236 into earlier lines of therapy, particularly in PDAC. Our third priority aimed to qualify our mutant selective inhibitors, RMC6291, a RAS on G12C selective inhibitor, and RMC9805, a RAS on G12D selective inhibitor, for late-stage development. We have made substantial progress against these priorities. We demonstrated compelling durability data, specifically progression-free survival and overall survival, in a cohort of patients with previously treated metastatic PDAC treated with RMC6236. Based on these results, we initiated our first global randomized phase III study in second-line treatment of patients with metastatic PDAC and are now actively dosing patients in this study. Last month, we shared encouraging safety, tolerability, and anti-tumor activity with RMC9805 in patients with KRAS G12b PDAC. We continue to advance and extend our pipeline, including RMC9805 and RMC6291, by exploring new combinations to inform the design of future pivotal studies in earlier lines of therapy and across multiple tumor types, including PDAC and non-small cell lung cancer. And there's more to come. We have a number of disclosure milestones ahead this quarter when we look forward to sharing updates across our RAS on inhibitor portfolio, including several approaches we're taking in non-small cell lung cancer, including both monotherapy and combinations. I'd now like to hand the call over to Dr. Steve Kelsey, our president of R&D. who will summarize the PDAC results we recently shared from the RMC-6236 and RMC-9805 monotherapy studies at the EORTC-NCI-AACR symposium, commonly referred to as the triple meeting. He'll also provide a brief overview of our plans in non-small cell lung cancer. Jack Anders, our CFO, will then provide a summary of the third quarter financial results before I share a few closing remarks and open the call to Q&A. Steve?